After Doubling in the Past 6 Months, Is This Stock a Buy?
It's been a wild 12 months for biotech company Bluebird Bio (NASDAQ: BLUE). Bluebird earned approval from the U.S. Food and Drug Administration (FDA) for Zynteglo and Skysona in August and September, respectively.